Blueprint Medicines Future Growth
Future criteria checks 5/6
Blueprint Medicines is forecast to grow earnings and revenue by 66.1% and 28% per annum respectively while EPS is expected to grow by 66.3% per annum.
Key information
66.1%
Earnings growth rate
66.3%
EPS growth rate
Biotechs earnings growth | 31.0% |
Revenue growth rate | 28.0% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 23 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 822 | 23 | 122 | 152 | 16 |
12/31/2025 | 599 | -161 | -63 | -29 | 17 |
12/31/2024 | 393 | -340 | -262 | -256 | 17 |
12/31/2023 | 249 | -507 | -453 | -437 | N/A |
9/30/2023 | 216 | -555 | -492 | -479 | N/A |
6/30/2023 | 226 | -554 | -515 | -505 | N/A |
3/31/2023 | 205 | -581 | -503 | -493 | N/A |
12/31/2022 | 204 | -558 | -511 | -502 | N/A |
9/30/2022 | 272 | -718 | -404 | -395 | N/A |
6/30/2022 | 230 | -702 | -367 | -361 | N/A |
3/31/2022 | 221 | -650 | -310 | -306 | N/A |
12/31/2021 | 180 | -644 | -302 | -299 | N/A |
9/30/2021 | 107 | -411 | -312 | -309 | N/A |
6/30/2021 | 828 | 340 | 407 | 409 | N/A |
3/31/2021 | 809 | 325 | 369 | 371 | N/A |
12/31/2020 | 794 | 314 | 384 | 387 | N/A |
9/30/2020 | 811 | 333 | 361 | 367 | N/A |
6/30/2020 | 75 | -395 | -340 | -327 | N/A |
3/31/2020 | 72 | -371 | -321 | -307 | N/A |
12/31/2019 | 67 | -348 | -292 | -278 | N/A |
9/30/2019 | 16 | -362 | -311 | -301 | N/A |
6/30/2019 | 8 | -340 | -291 | -284 | N/A |
3/31/2019 | 44 | -267 | -214 | -206 | N/A |
12/31/2018 | 45 | -237 | -188 | -175 | N/A |
9/30/2018 | 45 | -205 | -165 | -142 | N/A |
6/30/2018 | 52 | -170 | -138 | -114 | N/A |
3/31/2018 | 17 | -177 | -160 | -138 | N/A |
12/31/2017 | 21 | -148 | -135 | -120 | N/A |
9/30/2017 | 27 | -120 | N/A | -104 | N/A |
6/30/2017 | 26 | -99 | N/A | -96 | N/A |
3/31/2017 | 27 | -85 | N/A | -86 | N/A |
12/31/2016 | 28 | -72 | N/A | -25 | N/A |
9/30/2016 | 25 | -67 | N/A | -19 | N/A |
6/30/2016 | 22 | -63 | N/A | -13 | N/A |
3/31/2016 | 18 | -58 | N/A | -6 | N/A |
12/31/2015 | 11 | -56 | N/A | -32 | N/A |
9/30/2015 | 7 | -57 | N/A | -30 | N/A |
6/30/2015 | 3 | -56 | N/A | -26 | N/A |
3/31/2015 | 1 | -52 | N/A | -24 | N/A |
12/31/2014 | N/A | -46 | N/A | -35 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2L9 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.6%).
Earnings vs Market: 2L9 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 2L9 is expected to become profitable in the next 3 years.
Revenue vs Market: 2L9's revenue (28% per year) is forecast to grow faster than the German market (5.4% per year).
High Growth Revenue: 2L9's revenue (28% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2L9's Return on Equity is forecast to be high in 3 years time